Brainstorm Cell Therapeutics Inc. Short Interest Update
BCLI Stock | USD 1.89 0.10 5.03% |
Under 61% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
Brainstorm Cell Therapeutics Inc. saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 109,800 shares, a drop of 33.8 percent from the October 15th total of 165,900 shares. Currently, 2.3 percent of the companys shares are sold short. Based on
Read at thelincolnianonline.com
Brainstorm Cell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Brainstorm Cell Fundamental Analysis
We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Brainstorm Cell is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Brainstorm Cell Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.
Peers
Brainstorm Cell Related Equities
XFOR | X4 Pharmaceuticals | 10.87 | ||||
GBIO | Generation Bio | 6.74 | ||||
CRVS | Corvus Pharmaceuticals | 5.92 | ||||
HCWB | HCW Biologics | 2.78 | ||||
CUE | Cue Biopharma | 2.34 | ||||
PLX | Protalix Biotherapeutics | 2.30 | ||||
BCAB | Bioatla | 2.08 | ||||
CCCC | C4 Therapeutics | 2.07 | ||||
PASG | Passage Bio | 1.69 | ||||
ANTX | AN2 Therapeutics | 1.60 | ||||
GRI | GRI Bio | 1.41 | ||||
ALDX | Aldeyra | 1.26 | ||||
DAWN | Day One | 1.13 | ||||
CNTB | Connect Biopharma | 0.96 | ||||
TRVI | Trevi Therapeutics | 0.53 | ||||
HOWL | Werewolf Therapeutics | 0.75 | ||||
MREO | Mereo BioPharma | 1.38 | ||||
INZY | Inozyme Pharma | 1.45 | ||||
TERN | Terns Pharmaceuticals | 1.56 | ||||
EWTX | Edgewise Therapeutics | 1.72 | ||||
CELC | Celcuity LLC | 2.84 | ||||
CKPT | Checkpoint Therapeutics | 4.50 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Stocks Directory Find actively traded stocks across global markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |